Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)

被引：0
|
作者：
Kiver, Verena [1 ]
Hamilton, Erika [2 ]
Tsurutani, Junji [3 ]
Curigliano, Giuseppe [4 ]
Martin, Miguel [5 ]
O'sullivan, Ciara [6 ]
Sohn, Joo Hyuk [7 ]
Tryfonidis, Konstantinos [8 ]
Santarpia, Libero [9 ]
Yang, Shan [9 ]
Dieras, Veronique [10 ]
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[4] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[5] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[6] Mayo Clin, Rochester, MN USA
[7] Yonsei Canc Ctr, Seoul, South Korea
[8] Merck & Co Inc, Rahway, NJ USA
[9] Seagen Inc, Bothell, WA USA
[10] Eugene Marquis Ctr, Rennes, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
762
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [21] HER2CLIMB-04: phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+locally advanced or metastatic breast cancer with and without brain metastases (trial in progress)
    Hamilton, Erika
    Carey, Lisa
    Ramos, Jorge
    Chen, Yiyi
    Krop, Ian
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).
    Krop, Ian E.
    Carey, Lisa A.
    Ramos, Jorge
    Chen, Yiyi
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
    Curigliano, G.
    Mueller, V
    Borges, V
    Hamilton, E.
    Hurvitz, S.
    Loi, S.
    Murthy, R.
    Okines, A.
    Paplomata, E.
    Cameron, D.
    Carey, L. A.
    Gelmon, K.
    Hortobagyi, G. N.
    Krop, I
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Ramos, J.
    Feng, W.
    Winer, E.
    ANNALS OF ONCOLOGY, 2022, 33 (03) : 321 - 329
  • [24] Updated Results of Tucatinib versus Placebo in Combination with Trastuzumab and Capecitabine in Patients with pretreated metastatic HER2-positive Breast Cancer with CNS Metastases (HER2CLIMB)
    Greil, R.
    Lin, U. N.
    Murthy, K. R.
    Abramson, V
    Anders, C.
    Bachelot, T.
    Bedard, L. P.
    Borges, V
    Cameron, D.
    Carey, L.
    Chien, J. A.
    Curigliano, G.
    DiGiovanna, P. M.
    Gelmon, K.
    Hortobagyi, G.
    Hurvitz, S.
    Krop, I
    Loi, S.
    Loibl, S.
    Mueller, V
    Oliveira, M.
    Paplomata, E.
    Pegram, M.
    Slamon, D.
    Zelnak, A.
    Ramos, J.
    Feng, W.
    Winer, E.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (04) : E4 - E5
  • [25] HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
  • [26] HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
    Hurvitz, Sara
    Loi, Sherene
    O'Shaughnessy, Joyce
    Okines, Alicia
    Tolaney, Sara
    Sohn, Joo Hyuk
    Saura, Cristina
    Zhu, Xiaofu
    Cameron, David
    Bachelot, Thomas
    Hamilton, Erika
    Curigliano, Giuseppe
    Wolff, Antonio
    Harbeck, Nadia
    Masuda, Norikazu
    Vahdat, Linda
    Zaman, Khalil
    Valdes-Albini, Frances
    Block, Margaret
    Pluard, Timothy
    Tan, Tira
    Gawryletz, Chelsea
    Chan, Arlene
    Bedard, Philippe
    Yerushalmi, Rinat
    Xu, Binghe
    Tryfonidis, Konstantinos
    Schmitt, Michael
    Xie, Joan
    Borges, Virginia
    CANCER RESEARCH, 2024, 84 (09)
  • [27] The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+Metastatic Breast Cancer (TBCRC 062)
    Parsons, Heather
    Ruddy, Kathryn
    Morganti, Stefania
    Smith, Karen
    Attaya, Victoria
    Kallfelz, Eliza
    DeMeo, Michelle
    LaScala, Jamie
    Mertz, Shirley
    Pollastro, Teri
    Spears, Patricia
    Brufsky, Adam
    Dang, Chau
    Dent, Susan
    Elkhanany, Ahmed
    Gwin, WIlliam
    O'Sullivan, Ciara
    Miller, Kathy
    Nunnery, Sara
    Walsh, Elaine
    Storniolo, Anna Maria
    Tolaney, Sara
    Tayob, Nabihah
    Wolff, Antonio
    Winer, Eric
    Rimawi, Mothaffar
    Krop, Ian
    Lin, Nancy
    CANCER RESEARCH, 2024, 84 (09)
  • [28] A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+metastatic breast cancer progressing on trastuzumab therapy
    O'Shaughnessy, J.
    Blackwell, K. L.
    Burstein, H.
    Storniolo, A. M.
    Sledge, G.
    Baselga, J.
    Koehler, M.
    Laabs, S.
    Florance, A.
    Roychowdhury, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [30] Cost-effectiveness of pertuzumab in HER2+metastatic breast cancer
    Qian, Y.
    Durkee, B. Y.
    Pollom, E. L.
    King, M.
    Dudley, S. A.
    Shaffer, J. B.
    Chang, D. T.
    Gibbs, I. C.
    Goldhaber-Fiebert, J. D.
    Horst, K. C.
    CANCER RESEARCH, 2016, 76
12345